Last reviewed · How we verify
BAY86-5046_Interferon-beta-1b
Interferon-beta-1b binds to the interferon-alpha/beta receptor, activating a signaling cascade that modulates immune responses.
Interferon-beta-1b binds to the interferon-alpha/beta receptor, activating a signaling cascade that modulates immune responses. Used for Relapsing-remitting multiple sclerosis.
At a glance
| Generic name | BAY86-5046_Interferon-beta-1b |
|---|---|
| Sponsor | Bayer |
| Drug class | Interferon |
| Target | Interferon-alpha/beta receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 2 |
Mechanism of action
Interferon-beta-1b is a recombinant form of the human interferon-beta protein, which plays a crucial role in regulating immune responses and reducing inflammation.
Approved indications
- Relapsing-remitting multiple sclerosis
Common side effects
- Flu-like symptoms
- Fatigue
- Headache
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY86-5046_Interferon-beta-1b CI brief — competitive landscape report
- BAY86-5046_Interferon-beta-1b updates RSS · CI watch RSS
- Bayer portfolio CI